HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heptulla, R. A. Articles by Haymond, M. W. Search for Related Content PubMed PubMed Citation Articles by Heptulla, R. A. Articles by Haymond, M. W. Social Bookmarking                What's this?

The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes

From the Department of Pediatrics, Division of Diabetes and Endocrinology, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas

Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus–to–carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus–to–carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30–45 µg pramlintide with their usual insulin bolus–to–carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0–420 min was lower in control versus type 1 diabetic subjects (316 ± 5 vs. 929 ± 18 mg · h^–1 · dl^–1, P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC_{0–180 min} 470 ± 43 vs. 434 ± 48 mg · h^–1 · dl^–1, P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. G. Marrero, J. Crean, B. Zhang, T. Kellmeyer, M. Gloster, K. Herrmann, R. Rubin, N. Fineberg, and O. Kolterman Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes Diabetes Care, February 1, 2007; 30(2): 210 - 216. [Abstract] [Full Text] [PDF]

				E. A. Eugster, G. Francis, and and the Lawson-Wilkins Drug and Therapeutics Commi Position Statement: Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes Pediatrics, October 1, 2006; 118(4): e1244 - e1249. [Abstract] [Full Text] [PDF]

				M. Stadler, C. Anderwald, T. Karer, A. Tura, T. Kastenbauer, M. Auinger, C. Bieglmayer, O. Wagner, F. Kronenberg, P. Nowotny, et al. Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation: A sign of impaired {beta}-cell function? Diabetes Care, May 1, 2006; 29(5): 1031 - 1038. [Abstract] [Full Text] [PDF]